Athira Pharma Inc
Company Profile
Business description
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
Contact
18706 North Creek Parkway
Suite 104
BothellWA98011
USAT: +1 425 620-8501
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
26
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,770.60 | 25.40 | -0.29% |
| CAC 40 | 7,684.68 | 80.43 | -1.04% |
| DAX 40 | 23,516.23 | 255.22 | -1.07% |
| Dow JONES (US) | 42,197.79 | 769.83 | -1.79% |
| FTSE 100 | 8,850.63 | 34.29 | -0.39% |
| HKSE | 23,892.56 | 142.82 | -0.59% |
| NASDAQ | 19,406.83 | 255.66 | -1.30% |
| Nikkei 225 | 37,834.25 | 338.84 | -0.89% |
| NZX 50 Index | 12,552.87 | 96.23 | -0.76% |
| S&P 500 | 5,976.97 | 68.29 | -1.13% |
| S&P/ASX 200 | 8,547.40 | 17.70 | -0.21% |
| SSE Composite Index | 3,377.00 | 25.66 | -0.75% |